GoldmanJW,DvorkinM,ChenY,et al.Durvalumab,with or without tremelimumab,plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN):updated results from a randomised,controlled,open-label,phase 3 trial[J].Lancet Oncol,2021,22(1)...
14. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science 2009;324:1670-3. 15. Hobeika C, Rached G, Eid R, et al. ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment? Per Med 2018;15...
14. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science 2009;324:1670-3. 15. Hobeika C, Rached G, Eid R, et al. ALK-rearranged adenocarcinoma transformed to small-cell lung c...
These agents, constituting the “best of what's new” in SCLC, and discussed in this review following a brief overview of the classification, epidemiology, prognosis and current treatment of SCLC, include checkpoint inhibitors, antibody-drug conjugates, PARP inhibitors, epigenetic inhibitor/innate ...
Treatment 治疗 Chemotherapy 化疗 For all patients with SCLC, chemotherapy is an essential component of appropriate treatment. Adjuvant chemotherapy is...
7). Due to this particular biology of SCLC, combining ferroptosis induction with TRX pathway inhibition demonstrates high therapeutic efficacy in SCLC xenografts, GEMMs, patient-derived CDXs and identifies a unique SCLC patient subset with drastically improved prognosis. These data propose that combined...
CDKN1ANatural compoundPanobinostatSCLCSanguinarine chlorideObjectives:Small cell lung cancer (SCLC) is notorious for aggressive malignancy without effective treatment, and most patients eventually develop tumor progression with a poor prognosis. There is an urgent need for discovering novel antitumor agents or...
Despite advancements in diagnosis and treatment modalities, the prognosis for SCLC remains grim, primarily due to the rapid emergence of resistance to various therapeutic agents. Etoposide-platinum remains the most common initial treatment regimen for SCLC. While most patients initially respond to ...
in small cell lung cancer has been growing because of multiple factors, including the expanded use of surveillance brain magnetic resonance imaging (MRI), evolving controversies surrounding prophylactic cranial irradiation (PCI), integration of immunotherapy into management, and improvements in prognosis.9...
and lack of caspase-8, which is frequent in sclc. treatment of sclc cells with interferon-γ (ifn-γ) restored caspase-8 expression and facilitated trail-induced apoptosis. the overall loss of cell proliferation/viability upon treatment with the ifn-γ-trail combination was 70% compared to ...